Get the Stockscreener App
3.62
0.55%
-0.02
Ardelyx Inc stock is traded at $3.62, with a volume of 5.43M.
It is down -0.55% in the last 24 hours and down -19.56% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$3.64
Open:
$3.58
24h Volume:
5.43M
Relative Volume:
1.11
Market Cap:
$988.12M
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-11.55
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
-12.35%
1M Performance:
-19.56%
6M Performance:
-28.60%
1Y Performance:
-55.09%
1-Day Range:
$3.56
$3.71
1-Week Range:
$3.50
$4.18
52-Week Range:
$3.50
$8.1391
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
3.62 | 988.12M | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx LawsuitARDX - ACCESS Newswire
David Mott Bought 19% More Shares In Ardelyx - simplywall.st
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Ardelyx, Inc. Class Action: Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Ardelyx, Inc.(ARDX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Investors who lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Shareholders that lost money on Ardelyx, Inc. (ARDX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationARDX - ACCESS Newswire
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Ardelyx, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsARDX - ACCESS Newswire
(ARDX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Ardelyx downgraded at Raymond James after Q1 sales miss - MSN
Ardelyx presents data supporting IBSRELA at DDW 2025 - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc.ARDX - PR Newswire
Ardelyx First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Hedge Fund and Insider Trading News: Paul Tudor Jones, Warren Buffett, John Paulson Bill Ackman, Platinum Asset Management, Ardelyx Inc (ARDX), Stem Inc (STEM), and More - Insider Monkey
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digesti - GuruFocus
Ardelyx (ARDX) Highlights IBSRELA's Efficacy at Digestive Diseas - GuruFocus
Ardelyx (ARDX) Highlights IBSRELA's Efficacy at Digestive Disease Week Conference | ARDX Stock News - GuruFocus
Ardelyx showcases IBSRELA data at Digestive Disease Week - Investing.com
Ardelyx showcases IBSRELA data at Digestive Disease Week By Investing.com - Investing.com South Africa
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference - TradingView
Triple Study Results: IBSRELA IBS-C Drug Proves Safe for Teens and Nursing Mothers at DDW 2025 - Stock Titan
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2025 Earnings Call Transcript - Insider Monkey
Ardelyx Inc Reports Strong Growth Amid Challenges - MSN
Ardelyx targets $240M-$250M in IBSRELA 2025 sales amid strong Q1 growth - MSN
Analysts Have Been Trimming Their Ardelyx, Inc. (NASDAQ:ARDX) Price Target After Its Latest Report - Yahoo Finance
Raymond James cuts Ardelyx stock rating, lowers target to $11 By Investing.com - Investing.com Canada
Ardelyx (ARDX) Price Target Lowered by Citigroup to $10.00 | ARDX Stock News - GuruFocus
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ardelyx, Inc.(ARDX) Shareholders - ACCESS Newswire
Ardelyx Inc earnings missed by $0.06, revenue fell short of estimates - Investing.com Australia
Raymond James cuts Ardelyx stock rating, lowers target to $11 - Investing.com Australia
Ardelyx (ARDX) Faces Downgrade Amid Revenue Shortfall - GuruFocus
Ardelyx's Q1 Loss Widens; Shares Fall - marketscreener.com
Ardelyx stock downgraded at Raymond James (ARDX:NASDAQ) - Seeking Alpha
Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty (NASDAQ:ARDX) - Seeking Alpha
Stocks in play: SECURE Waste Infrastructure Corp. - The Globe and Mail
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Raymond James Downgrades Ardelyx to Outperform From Strong Buy, Adjusts Price Target to $11 From $13 - marketscreener.com
Ardelyx (ARDX) Downgraded by Raymond James Amid Sales Concerns | - GuruFocus
Ardelyx (ARDX) Price Target Reduced by Citi After Q1 Report | AR - GuruFocus
Ardelyx (ARDX) Downgraded by Raymond James Amid Sales Concerns | ARDX Stock News - GuruFocus
Ardelyx (ARDX) Price Target Reduced by Citi After Q1 Report | ARDX Stock News - GuruFocus
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
Ardelyx Inc (ARDX) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amid Market Challenges - Yahoo
Shareholders that Lost Money on Ardelyx, Inc. (ARDX) Should Contact Levi & Korsinsky About Pending Class ActionARDX - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Ardelyx (ARDX) Sees Revenue Surge in Q1 2025 - GuruFocus
Ardelyx Inc. Reports Strong Q1 2025 Growth - TipRanks
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):